DUB | Jotup

Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432

Retrieved on:

Tuesday, March 26, 2024

Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, DUB, Debiopharm, Therapy, Infection, USP1, DNA, DDR, Cancer, Drug discovery, Vaccine

The agreement will support the development of Debiopharm’s USP1 inhibitor programme, Debio 0432.

Key Points:

The agreement will support the development of Debiopharm’s USP1 inhibitor programme, Debio 0432.
Under the terms of the agreement, Ubiquigent will deploy its DUB-focused platform, combined with its deep understanding of the DUB field, to develop novel target engagement assays to support Debio-0432 as it approaches the clinic.
Currently, in late-stage preclinical development, Debio 0432 is a small molecule with best-in-class potential that could be deployed to combat multiple tumour types.
“We are delighted to enter this agreement with Debiopharm, supporting the development of its advanced USP1 inhibitor programme.

JetBlue Flights to the Emerald Isle Taking Off Today

Retrieved on:

Thursday, March 14, 2024

JetBlue (Nasdaq: JBLU) announced it has expanded its transatlantic offerings with new, nonstop flights taking off from New York and Boston today.

Key Points:

JetBlue (Nasdaq: JBLU) announced it has expanded its transatlantic offerings with new, nonstop flights taking off from New York and Boston today.
JetBlue has disrupted the transatlantic market since it first launched flights to London in 2021 offering a fresh, innovative, customer-focused experience without the historically high fares of legacy carriers.
Since then, JetBlue has expanded its portfolio to include Paris, Amsterdam and now Dublin, and will continue its growth in Europe with seasonal flights to Edinburgh and additional frequencies to Paris later this spring.
“JetBlue’s entrance into Dublin is set to introduce a new era of low fares and great service between Ireland and the Northeast,” said Joanna Geraghty, chief executive officer, JetBlue.

Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics

Retrieved on:

Monday, March 11, 2024

Biotechnology, Health, Science, Pharmaceutical, Research, Nanna, DUB, UPS, Therapy, Enzyme, Dub, Ubiquitin, Drug discovery, Pharmaceutical industry

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics (Nanna).

Key Points:

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics (Nanna).
Under the terms of the agreement, Ubiquigent will provide Nanna with access to its deubiquitylase (DUB) focused drug discovery platform to support the development of novel therapeutics for human disease targets selected by Nanna.
Dysregulation of DUB activity is implicated in many human diseases, highlighting their importance and promise for the development of novel therapeutics.
Jason Mundin, CEO of Ubiquigent, commented: “We are delighted to enter this latest agreement and look forward to supporting the team at Nanna Therapeutics.

JetBlue Announces Third Quarter 2023 Results

Retrieved on:

Tuesday, October 31, 2023

Operating revenue of $2.4 billion for the third quarter of 2023, down 8.2% year-over-year.

Key Points:

Operating revenue of $2.4 billion for the third quarter of 2023, down 8.2% year-over-year.
Operating expenses per available seat mile ("CASM") for the third quarter of 2023 decreased 3.3% year-over-year.
Operating expense per available seat mile, excluding fuel and related taxes, other non-airline operating expenses, and special items ("CASM ex-Fuel") for the third quarter of 2023 increased 5.9% (1) year-over-year.
Average fuel price in the third quarter of 2023 of $2.94 per gallon, including hedges.

Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on:

Thursday, November 2, 2023

CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.

Key Points:

CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.
Mission Therapeutics is a world leader in discovering and developing novel therapeutics which promote the removal of dysfunctional mitochondria to maintain cell health and function.
The American Society of Nephrology is a major organization working toward a goal of a world without kidney diseases and we are excited to have the opportunity to share our progress at this important conference.
A Phase II trial of MTX652 in patients at risk of acute kidney injury following cardiac surgery is planned to start in Q1 2024.

Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on:

Thursday, November 2, 2023

CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.

Key Points:

CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.
Mission Therapeutics is a world leader in discovering and developing novel therapeutics which promote the removal of dysfunctional mitochondria to maintain cell health and function.
The American Society of Nephrology is a major organization working toward a goal of a world without kidney diseases and we are excited to have the opportunity to share our progress at this important conference.
A Phase II trial of MTX652 in patients at risk of acute kidney injury following cardiac surgery is planned to start in Q1 2024.

Mission Therapeutics to Present at Michael J. Fox Foundation's 15th Annual Parkinson's Disease Therapeutics Conference

Retrieved on:

Tuesday, October 10, 2023

Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.

Key Points:

Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.
Fox Foundation (MJFF) is dedicated to accelerating a cure for Parkinson's Disease and improved therapies for those living with the condition today.
A major unmet need for Parkinson's Disease patients is a treatment that slows or prevents the progression of disease.
Mission Therapeutics is currently developing two DUB inhibitors: MTX325 (targeting the CNS) and MTX652 (peripheral) which can potentially be used to treat any disease driven by mitochondrial dysfunction.

Mission Therapeutics to Present at Michael J. Fox Foundation's 15th Annual Parkinson's Disease Therapeutics Conference

Retrieved on:

Tuesday, October 10, 2023

Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.

Key Points:

Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.
Fox Foundation (MJFF) is dedicated to accelerating a cure for Parkinson's Disease and improved therapies for those living with the condition today.
A major unmet need for Parkinson's Disease patients is a treatment that slows or prevents the progression of disease.
Mission Therapeutics is currently developing two DUB inhibitors: MTX325 (targeting the CNS) and MTX652 (peripheral) which can potentially be used to treat any disease driven by mitochondrial dysfunction.

PLAY's inaugural flight from Toronto takes off

Retrieved on:

Friday, June 23, 2023

John C. Munro Hamilton International Airport, Travel, DUB, AMS, Tax, CPH, EST, Sale, PLAY, Airbus, ARN, STN, KEF, Airline, Tourism, City

Toronto is PLAY's first destination in Canada and the fifth route in North America, joining New York, Washington, Boston and Baltimore.

Key Points:

Toronto is PLAY's first destination in Canada and the fifth route in North America, joining New York, Washington, Boston and Baltimore.
To celebrate PLAY's inaugural Toronto service, the airline has announced a limited-time flight sale, offering up to 25 per cent off fares for flights to Iceland (KEF), Amsterdam (AMS), Berlin (BER), Copenhagen (CPH), Stockholm (ARN), London (STN) and to Dublin (DUB), using the promo code: PLAYCANADA.
Impressively, the airline achieved an 87 per cent On-Time Performance rating in the month leading up to its inaugural flight to Toronto.
"Our inaugural flight out of Toronto is a tremendous milestone for PLAY," said Birgir Jónsson, CEO, PLAY.

Wesdome Drilling Southeast of Kiena Mine Identifies Potential Bulk Tonnage Underground Target; Returning 2.3 G/T Gold Over 72 M Core Length

Retrieved on:

Tuesday, May 23, 2023

Interim, Vein, DUB, Person, Geology, Mineral, Qualified person (European Union), Gold, WDO, National instrument, Hyperaccumulators table – 2 : Nickel, Chairperson, TSX, ALS, Disclosure, Mining, Uranium mining, Bob Shawkey

Since 2021, surface exploration at Kiena has been ramping up with the initial focus on exploration targets proximal to the Kiena Mine.

Key Points:

Since 2021, surface exploration at Kiena has been ramping up with the initial focus on exploration targets proximal to the Kiena Mine.
Most recently, surface drilling 2-3 kilometres southeast of the Kiena mine has identified wide zones of low grade gold mineralization potentially amenable to bulk tonnage underground mining similar to other operations in the region (see Figure 1).
Notably, this style of mineralization and alteration, hosted in diorite, is different from the Kiena Mine further to the west.
Highlights of the recent drilling northwest to the Shawkey 10 Zone are listed below and are summarized in Table 1.